Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Fuji
Farmers Insurance
Baxter
Teva

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,488,960

« Back to Dashboard

Which drugs does patent 6,488,960 protect, and when does it expire?

Patent 6,488,960 protects RAYOS and is included in one NDA.

This patent has fifteen patent family members in seven countries.

Summary for Patent: 6,488,960
Title: Corticosteroid formulation
Abstract:The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.
Inventor(s): Bardsley; Hazel Judith (Cambridge, GB)
Assignee: Arakis Ltd. (GB)
Application Number:09/936,586
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,488,960
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,488,960
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Drugs Protected by US Patent 6,488,960

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE ➤ Sign Up
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,488,960

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9905898Mar 15, 1999
PCT Information
PCT FiledMarch 14, 2000PCT Application Number:PCT/GB00/00924
PCT Publication Date:September 21, 2000PCT Publication Number: WO00/54780

International Family Members for US Patent 6,488,960

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 3179000 ➤ Sign Up
Australia 771088 ➤ Sign Up
Australia 8789501 ➤ Sign Up
Canada 2361503 ➤ Sign Up
Canada 2422991 ➤ Sign Up
European Patent Office 1158988 ➤ Sign Up
European Patent Office 1318816 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Argus Health
QuintilesIMS
Express Scripts
Merck
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.